Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy: A Review of Current Evidence

被引:0
作者
Sura Alwan
Jan M. Friedman
Christina Chambers
机构
[1] University of British Columbia,Department of Medical Genetics
[2] BC Women’s Hospital and Health Centre,Department of Pediatrics
[3] School of Medicine,undefined
[4] University of California,undefined
来源
CNS Drugs | 2016年 / 30卷
关键词
Autism Spectrum Disorder; Autism Spectrum Disorder; Fluoxetine; Paroxetine; Early Pregnancy;
D O I
暂无
中图分类号
学科分类号
摘要
Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressant medications worldwide. However, over the past decade, their use during pregnancy, a period of extreme vulnerability to the onset of depression, has become highly concerning to patients and their healthcare providers in terms of safety to the developing fetus. Exposure to SSRIs in pregnancy has been associated with miscarriage, premature delivery, neonatal complications, birth defects—specifically cardiac defects—and, more recently, neurodevelopmental disorders in childhood, specifically autism spectrum disorders. Studies addressing the effect of individual SSRIs indicate a small but higher risk for birth defects with maternal fluoxetine and paroxetine use. Though the excess in absolute risk is small, it may still be of concern to some patients. Meanwhile, antenatal depression itself is associated with adverse perinatal outcomes, and discontinuing antidepressant treatment during pregnancy is associated with a high risk of relapse of depression. Whether the observed adverse fetal effects are related to the mother’s medication use or her underlying maternal illness remains difficult to determine. It is important that every pregnant woman being treated with an SSRI (or considering such treatment) carefully weighs the risks of treatment against the risk of untreated depression for both herself and her child. The importance of recognizing a higher risk for the development of adverse outcomes lies in the potential for surveillance and possibly a timely intervention. Therefore, we recommend that pregnant women exposed to any SSRI in early pregnancy be offered options for prenatal diagnosis through ultrasound examinations and fetal echocardiography to detect the presence of birth defects. Tapering off or switching to other therapy in early pregnancy, if appropriate for the individual, may also be considered on a case-by-case basis.
引用
收藏
页码:499 / 515
页数:16
相关论文
共 50 条
  • [41] Selective serotonin reuptake inhibitors for children and adolescents.
    Kastelic E.A.
    Labellarte M.J.
    Riddle M.A.
    Current Psychiatry Reports, 2000, 2 (2) : 117 - 123
  • [42] Evaluation of akathisia in patients receiving selective serotonin reuptake inhibitors/serotonin and noradrenaline reuptake inhibitors
    Akgoz, Ismail
    Kara, Huseyin
    Ozcelik, Ozgen
    Donmez, Levent
    Eryilmaz, Mehmet
    Ozbey, Gul
    BEHAVIOURAL PHARMACOLOGY, 2024, 35 (08): : 460 - 463
  • [43] Use of Selective Serotonin Reuptake Inhibitors During Pregnancy and Risk of Major and Cardiovascular Malformations: An Update
    Tuccori, Marco
    Montagnani, Sabrina
    Testi, Arianna
    Ruggiero, Elisa
    Mantarro, Stefania
    Scollo, Carla
    Pergola, Alessandra
    Fornai, Matteo
    Antonioli, Luca
    Colucci, Rocchina
    Corona, Tiberio
    Blandizzi, Corrado
    POSTGRADUATE MEDICINE, 2010, 122 (04) : 49 - 65
  • [44] Serotonin reuptake inhibitors in pregnancy and the risk of major malformations: a systematic review
    Bellantuono, Cesario
    Migliarese, Giovanni
    Gentile, Salvatore
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2007, 22 (03) : 121 - 128
  • [45] The effects of selective serotonin reuptake inhibitors on male and female fertility: a brief literature review
    Milosavljevic, Jovana Z.
    Milosavljevic, Milos N.
    Arsenijevic, Petar S.
    Milentijevic, Milica N.
    Stefanovic, Srdan M.
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2022, 26 (01) : 43 - 49
  • [46] SELECTIVE SEROTONIN REUPTAKE INHIBITORS-INDUCED DELIRIUM: A CASE REVIEW
    Kogoj, Ales
    PSYCHIATRIA DANUBINA, 2014, 26 (03) : 277 - 280
  • [47] Selective Serotonin Reuptake Inhibitors and Operative Bleeding Risk A Review of the Literature
    Roose, Steven P.
    Rutherford, Bret R.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2016, 36 (06) : 704 - 709
  • [48] Bursts and the Efficacy of Selective Serotonin Reuptake Inhibitors
    Best, J.
    Nijhout, H. F.
    Reed, M.
    PHARMACOPSYCHIATRY, 2011, 44 : S76 - S83
  • [49] EVALUATION OF THE ANDROGENIC/ANTIANDROGENIC ACTIVITY OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS
    Pop, Anca
    Lupu, Diana
    Cherfan, Julien
    Kiss, Bela
    Loghin, Felicia
    FARMACIA, 2015, 63 (03) : 343 - 348
  • [50] Selective Serotonin Reuptake Inhibitors for Stroke Recovery
    Legg, Lynn A.
    Tilney, Russel
    Hsieh, Cheng-Fang
    Wu, Simiao
    Lundstrom, Erik
    Rudberg, Ann-Sofie
    Kutlubaev, Mansur A.
    Dennis, Martin
    Soleimani, Babak
    Barugh, Amanda
    Hackett, Maree L.
    Hankey, Graeme J.
    Mead, Gillian E.
    STROKE, 2020, 51 (08) : E142 - E143